Copeptin: a neuroendocrine biomarker of COVID-19 severity.
Biomark Med
; 16(8): 589-597, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1855268
ABSTRACT
Aim:
To investigate the change in a serum level of copeptin, a neuroendocrine biomarker, in differentiating grades of COVID-19 severity on admission time and to find its diagnostic potential. Materials &Methods:
160 COVID-19 patients were classified according to disease severity into 80 mild to moderate and 80 severe patients. Serum copeptin level was assessed by ELISA on their admission time. Besides, serum CRP, ferritin and D-dimer were estimated.Results:
Severe COVID-19 patients showed higher serum copeptin level in comparison to mild to moderate cases, with diagnostic potential to distinguish disease severity with 93.33% sensitivity and 100% specificity at cutoff value >18.5 Pmol/l.Conclusion:
Serum copeptin was remarkably increased with COVID-19 severity with reasonable differentiation potential for recently admitted patients.
We conducted a biochemical study on the role of copeptin a biomarker of acute stress due to COVID-19 infection in classification of COVID-19 severity on admission over 160 adult patients. Copeptin was highly elevated in severe cases more than the mild to moderate ones. So, it may be an early marker in admission departments to ease early clinical decisions and medical intervention.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Biomark Med
Journal subject:
Biochemistry
/
Medicine
Year:
2022
Document Type:
Article
Affiliation country:
Bmm-2021-1100
Similar
MEDLINE
...
LILACS
LIS